Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 183

1.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Apr 18. pii: ciw236. [Epub ahead of print]

PMID:
27090986
2.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS.

Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14.

PMID:
27036991
3.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. No abstract available.

PMID:
26977746
4.

Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.

Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):133-7. doi: 10.1097/QAI.0000000000000936.

5.

Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Gianella S, Ginocchio CC, Daar ES, Dube MP, Morris SR.

BMC Infect Dis. 2016 Jan 25;16:24. doi: 10.1186/s12879-016-1356-y.

6.

Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.

Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S.

AIDS. 2016 Jan;30(2):193-201. doi: 10.1097/QAD.0000000000000964.

PMID:
26558730
7.

Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.

Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R; CCTG 592 Team.

AIDS Behav. 2016 Jun;20(6):1173-81. doi: 10.1007/s10461-015-1215-7.

PMID:
26487300
8.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR.

Sci Rep. 2015 Aug 24;5:13179. doi: 10.1038/srep13179.

9.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

PMID:
26148204
10.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410. eCollection 2015.

11.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):168-77. doi: 10.1097/QAI.0000000000000557.

12.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113. eCollection 2015 Jan.

13.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM.

J Comp Eff Res. 2015;4(2):101-14. doi: 10.2217/cer.14.69. Review.

PMID:
25825840
14.

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.

Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

Open Forum Infect Dis. 2014 Apr 16;1(1):ofu003. doi: 10.1093/ofid/ofu003. eCollection 2014 Mar.

15.

A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H.

AIDS Behav. 2015 Jun;19 Suppl 2:156-62. doi: 10.1007/s10461-014-0990-x.

16.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA; HIV Neuroimaging Consortium.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35. doi: 10.1097/QAI.0000000000000532.

17.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

18.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.

19.

Antiretroviral therapy: treatment-experienced individuals.

Calvo KR, Daar ES.

Infect Dis Clin North Am. 2014 Sep;28(3):439-56. doi: 10.1016/j.idc.2014.06.005. Epub 2014 Jul 8. Review.

PMID:
25151565
20.

Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.

Wyatt CM, Kitch D, Gupta SK, Tierney C, Daar ES, Sax PE, Ha B, Melbourne K, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36-44. doi: 10.1097/QAI.0000000000000245.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk